What's going on with the NIB share price today?

We now know when the private health insurer's long-serving CEO is stepping down.

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is underperforming on Thursday morning.

At the time of writing, the private health insurance provider's shares are trading largely flat.

As a comparison, the ASX 200 index is up 0.65%.

Why is the NIB share price underperforming?

The catalyst for this underperformance has been confirmation that the company's long-serving managing director and CEO is stepping down in a touch over two months.

According to the release, Mark Fitzgibbon will formally resign from the role on 30 November. Mr Fitzgibbon joined NIB in 2002 as its leader and took the company through its demutualisation and listing on the ASX in 2007.

It is worth noting that this isn't brand new information. In July, the company revealed that Fitzgibbon was planning to hand in his resignation in September.

At the time, the company stated:

From modest beginnings in 1952, today nib provides more than 1.6 million Australian and New Zealand residents with private health insurance; it looks after the health and wellbeing needs of more than 200,000 international students and workers; nib is Australia's third-largest travel insurer, a 24-7 global business; and it helps around 40,000 participants in Australia's disability sector. For the last 22 years, Mark has been at the helm of a company that has undergone a remarkable transformation, and that transformation is a great credit to his leadership.

New CEO

Replacing Mark Fitzgibbon will be Ed Close. He is currently chief executive of NIB's core Australian Residents Health Insurance (arhi) business. In this role, Close oversees product development, claims, customer services, and leads NIB's strategic partnerships with brokers and white label partners.

NIB chair, David Gordon, described Ed Close as an "exceptional leader" and "able to bring NIB's strategy to life and deliver continued strong growth."

Should you invest?

Goldman Sachs is feeling positive about NIB and sees value in its share price.

According to a recent note, the broker has a buy rating and $6.60 price target on the company's shares.

Commenting on its buy rating, the broker said:

NHF is a private health insurer with operations across Australian residents health insurance, New Zealand health insurance, International health insurance and Travel. We are Buy-rated on NHF given: 1) It offers defensive exposure to the private health insurance sector 2) The claims environment (utilisation / inflation) has been relatively manageable 3) NHF policyholder growth has been better than industry, 4) Expense buffers available to support margins and 5) Strong approved rate increases.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Healthcare Shares

Here's the earnings forecast out to 2030 for CSL shares

How healthy will the profit growth be in the coming years?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »